Core areas of immuno-oncology research

Explore the therapeutic and diagnostic technologies driving cancer immunotherapy, from immune checkpoint inhibitors and CAR T-cell therapy to antibody-drug conjugates, cancer vaccines, bispecific antibodies, and liquid biopsy.

Immuno-oncology (IO) research is transforming cancer treatment through therapies that activate, engineer, or redirect immune responses against tumors, as well as technologies that enable precise disease monitoring and patient stratification.

Discover the major therapeutic and diagnostic approaches shaping modern cancer immunotherapy, including immune checkpoint inhibitors, cell and gene therapies, antibody-drug conjugates, cancer vaccines, monoclonal and bispecific antibodies, and liquid biopsy.

Immune checkpoint inhibitors

Monoclonal antibodies that block inhibitory immune pathways such as CTLA-4, PD-1/PD-L1, LAG-3, and TIGIT, restoring T-cell-mediated antitumor responses.

/content/danaher/abcam/ko/technical-resources/research-areas/immuno-oncology/core-immuno-oncology-modalities1/immune-checkpoint-inhibitors

Cell and gene therapy: CAR T-cell therapy and chimeric antigen receptors (CARs)

Engineered immune cells designed to recognize and destroy cancer cells through synthetic receptors or genetic modifications that enhance antitumor activity.

/content/danaher/abcam/ko/technical-resources/research-areas/immuno-oncology/core-immuno-oncology-modalities1/chimeric-antigen-receptors

Antibody-drug conjugates (ADCs)

Targeted therapeutics that combine the specificity of monoclonal antibodies with potent cytotoxic agents to selectively eliminate tumor cells.

/content/danaher/abcam/ko/technical-resources/research-areas/immuno-oncology/core-immuno-oncology-modalities1/antibody-drug-conjugates

Cancer vaccines

Therapies that stimulate adaptive immune responses against tumor-associated or tumor-specific antigens using peptide, viral vector, dendritic cell, DNA, or mRNA platforms.

/content/danaher/abcam/ko/technical-resources/research-areas/immuno-oncology/core-immuno-oncology-modalities1/cancer-vaccines

Monoclonal and bispecific antibodies

Antibody-based therapies that block signaling pathways, recruit immune effector functions, or redirect immune cells toward tumor targets through dual-target binding.

/content/danaher/abcam/en-us/stories/articles/bispecific-antibodies-engineering-the-next-wave-of-targeted-therapeutics

Liquid biopsy

Minimally invasive analysis of tumor-derived biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles, to monitor disease progression, treatment response, and resistance.

/content/danaher/abcam/en-us/knowledge-center/oncology/liquid-biopsy-for-non-invasive-cancer-detection